文章：

不可手术III期非小细胞肺癌治疗中免疫调节策略的批判性评述

A Critical Review of Immunomodulation in the Management of Inoperable Stage III NSCLC

原文发布日期：30 May 2025

DOI: 10.3390/cancers17111829

类型: Article

开放获取: 是

英文摘要：

The current standard of care for inoperable stage III non-small cell lung cancer (NSCLC) is concurrent chemotherapy and radiation therapy with consolidation durvalumab. Despite this approach, about 50% of patients will experience disease recurrence, with about half of recurrence events occurring at distant metastatic sites. In this review, the authors performed a structured analysis of the available clinical trial data and literature related to the treatment of this disease. The authors discuss the detriments and merits of several of these trials and explore clinical and preclinical data that contribute to the growing body of literature supporting a future with new approaches, including new techniques in radiation therapy, sequencing, and agents. Upcoming trials may illuminate a path towards better outcomes for patients in this setting.

摘要翻译： 

对于无法手术的III期非小细胞肺癌（NSCLC），当前的标准治疗方案是同步放化疗联合度伐利尤单抗巩固治疗。尽管采用这一方法，仍有约50%的患者会出现疾病复发，其中约半数复发事件发生在远处转移部位。本文作者对现有临床试验数据及相关文献进行了系统性分析，探讨了多项临床试验的局限性与优势，并整合临床及临床前研究数据，这些研究正不断积累证据支持未来采用新治疗策略，包括放射治疗新技术、治疗顺序优化及新型药物。即将开展的临床试验或将为改善此类患者预后指明方向。

原文链接：

A Critical Review of Immunomodulation in the Management of Inoperable Stage III NSCLC